How to Read a GLP-1 Telehealth Provider's Terms Before You Sign Up: A Clinical Checklist

The marketing pages for telehealth GLP-1 programs share a great deal. Most feature some version of the same clinical statistics, similar price anchors, and nearly identical “start today” calls to action. What varies significantly is what patients find once they move past the landing page and into the actual clinical terms, subscription structures, cancellation policies, and physician oversight models. Reading these carefully before enrolling is not paranoia—it is basic consumer due diligence on a clinical decision that affects both your health and your finances.

This article is a structured checklist of the questions that matter, organized by category. Work through it before providing payment information to any GLP-1 telehealth program.

1. Physician Oversight and Licensing

The most fundamental clinical question is whether the program employs licensed physicians who will personally review your case and make prescribing decisions. Some programs use the label “physician-supervised” while routing intake through nurse practitioners or physician assistants who operate under physician oversight protocols rather than direct physician review. This is legally permissible in many states, but it is not the same as a board-certified physician reading your intake data.

2. Medication Type and Sourcing

The program’s terms should clearly state whether they dispense FDA-approved brand-name medications (Wegovy, Zepbound, Ozempic, Mounjaro) or compounded medications. If compounded, they should identify the pharmacy and its licensure status. The regulatory environment for compounded semaglutide changed significantly in 2025; a program that does not clearly disclose which type of medication it dispenses is not operating transparently.

Also review whether the program can switch you between compounded and brand-name medications if the regulatory environment or supply chain changes—and whether that switch would change your monthly cost or require re-authorization.

3. Subscription and Billing Structure

GLP-1 telehealth programs use several billing models, and the differences matter:

Look specifically for: (1) when the billing cycle starts relative to when you actually receive medication; (2) whether the price shown is for the introductory dose (often 0.25 mg or 2.5 mg, the cheapest) or for the maintenance dose you will reach after several months; and (3) whether price increases are disclosed in the terms or can occur at the company’s discretion.

4. Cancellation and Refund Terms

The cancellation policy is where programs vary most dramatically. Review these specific terms before enrolling:

• Cancellation window: Can you cancel before the first shipment ships without charge? Many programs charge the first month immediately on enrollment and ship within 24–48 hours, leaving almost no cancellation window.
• Mid-cycle cancellation: If you cancel mid-month, do you receive a prorated refund or forfeit the remainder?
• Medication return policy: Prescription medications generally cannot be returned. Programs that suggest you can return unused medication for a refund are unlikely to honor this for injectable medications.
• Physician visit fees: If the evaluation has already occurred, the physician visit fee is typically non-refundable even if you decide not to proceed with the program. This is standard and not itself a red flag, but it should be understood in advance.

5. Follow-Up and Clinical Continuity

A program that evaluates you, sends medication, and then provides no structured follow-up is not delivering physician-supervised care—it is delivering a prescription and a product. Legitimate clinical oversight of GLP-1 therapy requires:

• Scheduled follow-up appointments at defined intervals (typically every 4–8 weeks during dose escalation)
• A mechanism for contacting a clinician between appointments when side effects occur
• Response protocols for dose-limiting adverse events (guidance on whether to slow escalation, take a dose holiday, or discontinue)
• Periodic reassessment of clinical response (weight, vital signs, relevant labs)

Ask directly: What happens if I have significant nausea at week 3 and need guidance? The answer reveals a great deal about the program’s actual clinical model.

6. Data Privacy and Information Sharing

GLP-1 telehealth programs collect detailed health information: weight history, diagnoses, medications, lab values. Review the privacy policy specifically for:

• Whether de-identified health data is shared with or sold to third parties, including insurers, data brokers, or pharmaceutical companies
• Whether the program’s app or platform shares any behavioral data (usage patterns, app activity) with analytics or advertising partners
• How long health records are retained after account closure
• Whether the program is a HIPAA-covered entity and what that means for their data handling obligations

7. Red Flags That Should Give You Pause

Certain language or policy patterns appear in programs that are operating at the margins of legitimate clinical practice. These warrant serious scrutiny:

• Prescriptions confirmed within minutes of form completion, with no disclosure of who reviewed the clinical information
• No physician name, license number, or state of licensure disclosed at any point in the enrollment process
• Guarantee of prescription regardless of clinical profile (“If you qualify for our program, you will receive a prescription” with no qualification criteria disclosed)
• Medication prices that are implausibly below market rate for verified pharmaceutical products
• Terms that include mandatory arbitration for all disputes, with very short windows (30 days or less) to file
• No disclosed physical address or registered business entity information